LYB
36
-10
COF
58
-2
EXC
61
-2
EL
46
-6
CB
53
2
TXN
36
-12
TGT
59
-3
ORLY
60
-4
SNA
53
-2
PFE
19
-6
EIX
56
2
MMM
26
-2
MDT
53
-3
HD
25
-10
WAT
49
-3
DFS
62
-5
CCL
44
4
PPL
55
-2
PNR
62
2
SLB
46
2
LYB
36
-10
COF
58
-2
EXC
61
-2
EL
46
-6
CB
53
2
TXN
36
-12
TGT
59
-3
ORLY
60
-4
SNA
53
-2
PFE
19
-6
EIX
56
2
MMM
26
-2
MDT
53
-3
HD
25
-10
WAT
49
-3
DFS
62
-5
CCL
44
4
PPL
55
-2
PNR
62
2
SLB
46
2
Financhill
Back

Keros Therapeutics Quote, Financials, Valuation and Earnings

Election Shock on August 19th?

Click here now to see the evidence I've gathered.
Sell
22

KROS
Keros Therapeutics

Last Price:
54.22
Seasonality Move:
-16.78%

7 Day Trial

ALL ACCESS PASS

$ 7

This trade could move overnight Thursday!

Access my free presentation on these overnight trades right here

Keros Therapeutics Price Quote

$54.22
+0.03 (+-3.59%)
(Updated: April 26, 2024 at 6:09 AM ET)

Keros Therapeutics Key Stats

Sell
22
Keros Therapeutics (KROS) is a Sell
Day range:
$53.24 - $55.05
52-week range:
$27.02 - $73.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
5.87%
Volume:
260.4K
Avg. volume:
339.4K
1-year change:
23.55%
Market cap:
$1.9B
Revenue:
$151K
EPS:
$-5.2

How Much Does Keros Therapeutics Make?

Data Unavailable

Is Keros Therapeutics Growing As A Company?

Data Unavailable

Keros Therapeutics Stock Price Performance

What Is Keros Therapeutics 52-Week High & Low?

Keros Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Keros Therapeutics?

Is Keros Therapeutics Cash Flow Positive?

  • What Is KROS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$124.5M
  • What Is Keros Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $179M
  • What Is Keros Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$2.5M

Keros Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    KROS return on invested capital is -48.21%
  • What Is Keros Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -43.87%
  • What Is KROS Return On Equity?
    ROE is a measure of profitability and is -48.21%

Keros Therapeutics Earnings Date & Stock Price

Keros Therapeutics Competitors

  • Who Are Keros Therapeutics's Competitors?
    Below is a list of companies who compete with Keros Therapeutics or are related in some way:
    • Morphic Holding Inc (MORF)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Regeneron Pharmaceuticals Inc (REGN)
    • Scholar Rock Holding Corp (SRRK)

Keros Therapeutics Dividend Yield

Data Unavailable

Keros Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 3.68%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 88.11
Upside from Last Price: 62.6%

Major Shareholders

  • How many KROS shares are owned by institutional investors?
    42M KROS shares are owned by institutional investors
  • How many KROS shares are owned by insiders?
    372.2K KROS shares are owned by insiders